minimum inhibitory concentration – Page 2

Establishment of epidemiological cutoff values for Fonsecaea pedrosoi, the primary etiologic agent of chromoblastomycosis, and eight antifungal medications

mycolabadmin

Chromoblastomycosis is a serious fungal skin infection caused by a fungus called Fonsecaea pedrosoi, particularly affecting people in tropical regions and those in poverty. Researchers from multiple countries tested 148 samples of this fungus against eight different antifungal medications to determine how well each drug works. They established baseline measurements that doctors can use to determine if a patient’s fungal infection might not respond well to standard treatments, helping guide better treatment decisions.

Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis

mycolabadmin

This study tested a new antifungal drug called SF001 against a serious infection called fusariosis in mice. SF001 performed as well as the current standard treatment (amphotericin B) but with better safety profiles. The drug successfully reduced fungal infections in organs and improved survival rates in infected mice without showing signs of toxicity at higher doses.

Investigation of the antifungal activity of panobinostat, tamoxifen, and miltefosine alone and in combination with some conventional antifungal drugs against fluconazole-resistant Candida species

mycolabadmin

Researchers tested whether three cancer drugs (panobinostat, tamoxifen, and miltefosine) could enhance the effectiveness of common antifungal medications against drug-resistant yeast infections. When combined with antifungals, some of these cancer drugs showed promise in killing resistant Candida species, though the effectiveness varied depending on which type of yeast was being treated. These findings suggest that combination therapies using already-approved drugs could help treat difficult fungal infections in cancer patients.

A Unique Case of Fungal Endometritis Caused by Aspergillus quadrilineatus in an Immunocompetent Woman and Literature Review

mycolabadmin

A 64-year-old woman experienced persistent vaginal bleeding for three months, which was found to be caused by a rare fungal infection (Aspergillus quadrilineatus) in her uterus. Through tissue examination and molecular testing, doctors identified the fungus and found it was sensitive to common antifungal medications. The patient was successfully treated with antifungal medication combined with surgical cleaning of the uterus, making a complete recovery. This case highlights that fungal infections should be considered when patients have abnormal vaginal bleeding, even if they appear otherwise healthy.

Severe Saprochaete capitata fungemia presenting as micafungin breakthrough hepatosplenic lesions in an immunocompromised patient: case report

mycolabadmin

A 70-year-old woman with blood cancer developed a serious fungal blood infection caused by Saprochaete capitata, a rare soil fungus, despite taking preventive antifungal medication. The infection spread to her liver and spleen, creating multiple lesions and a dangerous aneurysm. Doctors successfully treated her with a combination of three antifungal drugs, particularly voriconazole, which proved more effective than the initial preventive medication. This case highlights how rare fungi can cause severe infections in cancer patients and the importance of recognizing when standard preventive treatments are not working.

Candida tropicalis Fungal Keratitis: A Case Report and Literature Review

mycolabadmin

A 66-year-old patient with a long history of corneal problems developed a serious eye infection caused by a fungus called Candida tropicalis. Doctors identified the infection through laboratory tests and treated it successfully with antifungal medications. This is the first documented case of this particular fungal infection in Morocco and highlights the importance of testing for fungal infections in patients with existing eye problems.

Evaluation of antifungal effect of amphotericin B in comparison with nystatin on Candida species derived from patients undergoing head-and-neck radiotherapy

mycolabadmin

This study compared two antifungal medications (nystatin and amphotericin B) for treating oral yeast infections in cancer patients receiving head-and-neck radiotherapy. Researchers tested how well each drug worked against different Candida yeast species before and during radiation treatment. The results showed that nystatin was more effective than amphotericin B at killing the yeasts, with nystatin working against all yeast species tested, while amphotericin B had reduced effectiveness against some Candida albicans strains.

Analysis of Susceptibility and Drug Resistance of Antifungal Agents in Aspergillosis and Mucormycosis Patients: A Systematic Review

mycolabadmin

This comprehensive study analyzed how well five major antifungal drugs work against common disease-causing fungi like Aspergillus and Mucorales. Researchers reviewed 96 studies examining over 16,000 fungal samples to understand resistance patterns. The findings show that different fungi respond better to different drugs—for example, Aspergillus flavus responds well to voriconazole, while amphotericin B works best against other Aspergillus species. This information helps doctors choose the most effective treatments for fungal infections in vulnerable patients.

Toward the consensus of definitions for the phenomena of antifungal tolerance and persistence in filamentous fungi

mycolabadmin

Scientists have proposed clear definitions and testing methods for two drug-resistance phenomena in fungi that cause infections. Unlike typical drug resistance, tolerance and persistence allow fungi to survive antifungal medications but in different ways: tolerance affects most spores while persistence affects only a small fraction. By standardizing how these phenomena are tested using fungal spores and measuring how quickly drugs kill them, researchers can better understand treatment failures and develop better therapies.

Targeted long-read sequencing analysis and antifungal susceptibility profiles of Sporothrix schenckii isolates from Thailand

mycolabadmin

Researchers in Thailand studied a fungal infection called sporotrichosis by using advanced DNA sequencing technology to identify the exact species and understand how different strains are related to each other. They found that while current treatment options work, some strains are becoming resistant to the main drug used (itraconazole). The study shows that a newer, faster DNA sequencing method can be just as reliable as traditional methods for identifying these dangerous fungi and tracking how they spread between cats and humans.

Research Keyword: minimum inhibitory concentration